Apellis Pharmaceuticals to Join Key Investor Conferences
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has announced its participation in several important investor conferences taking place this September. These events provide a valuable opportunity for the company to connect with investors and stakeholders within the healthcare sector.
Upcoming Conference Details
Apellis will be featured at prominent healthcare conferences, where it will share insights into its innovative therapies and research advancements. The upcoming events include:
- Wells Fargo Annual Healthcare Conference 2024: Fireside chat on Thursday at 9:30 a.m. ET.
- Baird 2024 Global Healthcare Conference: Fireside chat on Wednesday at 9:05 a.m. ET.
Investors can tune in to live broadcasts of the conference webcasts, which will be available on the company’s website under the 'Events and Presentations' section. Additionally, replays of these presentations will be accessible for about 90 days after each event, ensuring that stakeholders have multiple ways to access this vital information.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicated to developing transformative treatments for serious health conditions. The company combines advanced scientific research with a commitment to compassionate care, aiming to provide patients with therapies that meet unmet medical needs.
Innovative Therapeutic Solutions
Apellis has launched a new class of complement medicine, representing the first major advancement in this field in over 15 years. The company currently offers two approved therapies that target the complement C3 protein, a vital component of the body’s immune response.
One of Apellis’ notable products is the only available treatment for geographic atrophy, a leading cause of irreversible vision loss. This groundbreaking therapy signifies a major advancement in the fight against blindness-causing diseases, highlighting the company’s commitment to eye health. Moreover, Apellis is investigating additional applications of C3 targeting across various disease areas, including rare and neurological conditions, further demonstrating its dedication to innovative medicine.
Investor Relations and Communication
Apellis Pharmaceuticals places a strong emphasis on transparency and accessibility in its communications with investors. For inquiries, investors can reach out to Meredith Kaya via email or through the company’s main contact number. Engaging with stakeholders is vital for fostering growth and building trust within the investment community.
If you want to stay informed about Apellis’ developments and announcements, you can follow the company on social media platforms like Twitter and LinkedIn, where they regularly post insights and updates about their innovative initiatives.
Future Directions
Looking forward, Apellis Pharmaceuticals plans to broaden its portfolio and explore new therapeutic avenues that utilize its unique scientific approach. The ongoing development of C3-targeted therapies showcases the potential for transformative effects on the treatment landscape for chronic conditions, paving the way for continued progress in the biopharmaceutical industry.
Frequently Asked Questions
What are the key investor conferences Apellis is participating in?
Apellis Pharmaceuticals will take part in the Wells Fargo Annual Healthcare Conference and the Baird 2024 Global Healthcare Conference.
What is Apellis Pharmaceuticals known for?
Apellis is recognized for its innovative therapies that target the complement system, especially its treatments for geographic atrophy.
How can investors access the conference webcasts?
Investors can access live webcasts and replays of the conferences through the 'Events and Presentations' section on the company's website.
Who is the investor contact at Apellis Pharmaceuticals?
The investor contact is Meredith Kaya, who can be reached at meredith.kaya@apellis.com or by phone at 617.599.8178.
Where can I find more information about Apellis Pharmaceuticals?
Additional information is available on Apellis Pharmaceuticals' official website and through their social media channels on Twitter and LinkedIn.